XML Template (2009) [5.9.2009–3:06pm] [1–12]
{TANDF_FPP}CMO/CMO_A_370883(NEW).3d (CMO) [First Proof]
Current Medical Research and Opinion
C213
Volume 25, Number 3 2008
Eli Lilly and Company, GlaxoSmithKline, Medac Germany and
ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol
Essex Pharma Germany.
2000;18:1062-7
The authors would like to thank Dr Melanie Down
18. Safra T, Menczer J, Bernstein R, et al. Efficacy and toxicity of weekly topo-
of Discovery London who provided medical writing services,
tecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol
with funding supportprovidedby GlaxoSmithKline. Theauthors
Oncol 2007;105:205-10
19. ten Bokkel Huinink W, Gore M, et al. Topotecan versus paclitaxel for the
accept sole responsibility for the accuracy of the manuscript, and
treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:
also had final responsibility for the decision to submit for
2183-93
publication.
20. ten Bokkel Huinink W, Lane SR, Ross GA. Long-term survival in a phase III,
randomised study of topotecan versus paclitaxel in advanced epithelial ovar-
ian carcinoma. Ann Oncol 2004;15:100-3
21. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carci-
References
noma: a randomized phase III study of pegylated liposomal doxorubicin versus
topotecan. J Clin Oncol 2001;19:3312-22
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: Cancer J Clin
22. Meier W, Dubois A, Kuhn W, et al. Topotecan vs treosulfan in recurrent
2008;58:71-96
ovarian cancer (OC) after initial therapy with platinum and paclitaxel. A pro-
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and
spective randomized phase III study. Proc Am Soc Clin Oncol 2003;
mortality in Europe in 2006. Ann Oncol 2007;18:581-92
22:Abstract 1810
3. Ahmad T, Gore M. Review of the use of topotecan in ovarian carcinoma.
23. Vandenput I, Amant F, Neven P, et al. Effectiveness of weekly topotecan in
Expert opinion on pharmacotherapy 2004;5:2333-40
patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer
4. Obel J, Fleming G. Topotecan in the treatment of ovarian cancer. Expert Rev 2007;17:83-7
Obstet Gynecol 2006;1:149-58 24. Clarke-Pearson DL, Van Le L, Iveson T, et al. Oral topotecan as single-agent
5. Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur second-line chemotherapy in patients with advanced ovarian cancer. J Clin
J Surg Oncol 2006;32:875-86 Oncol 2001;19:3967-75
6. Thigpen JT, Aghajanian CA, Alberts DS, et al. Role of pegylated liposomal 25. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous
doxorubicin in ovarian cancer. Gynecol Oncol 2005;96:10-18 topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer
7. Abushahin F, Singh DK, Lurain JR, et al. Weekly topotecan for recurrent 2002;38:57-63
platinum resistant ovarian cancer. Gynecol Oncol 2008;108:53-7 26. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of prolonged
8. Kristensen GB, Vergote I, Stuart G, et al. First-line treatment of ovarian cancer administration of oral topotecan in platinum/taxane-refractory ovarian,
FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/car- fallopian tube, and primary peritoneal cancers. Gynecol Oncol 2004;95:
boplatin. Int J Gynecol Cancer 2003;13(Suppl 2):172-7 109-13
9. du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to 27. Tillmanns TD, Buller R, Stewart CF, et al. Daily oral topotecan: Utilization of a
carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a metronomic dosing schedule to treat recurrent or persistent solid tumors.
prospectively randomized gynecologic cancer intergroup trial by the J Clin Oncol 2008;26:Abstract 2571
Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study 28. Gralla RJ. Quality-of-life considerations in patients with advanced lung
Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers cancer: effect of topotecan on symptom palliation and quality of life.
Ovariens. J Clin Oncol 2006;24:1127-35 Oncologist 2004;9(Suppl 6):14-24
10. du Bois A, Belau A, Wagner U, et al. A phase II study of paclitaxel, carboplatin, 29. Armstrong DK, Spriggs D, Levin J, et al. Hematologic safety and tolerability of
and gemcitabine in previously untreated patients with epithelial ovarian topotecan in recurrent ovarian cancer and small cell lung cancer: an inte-
cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). Gynecol Oncol grated analysis. Oncologist 2005;10:686-94
2005;96:444-51 30. Herzog TJ. Update on the role of topotecan in the treatment of recurrent
11. Hoskins PJ, Vergote I, Stuart G, et al. A phase III trial of cisplatin plus ovarian cancer. Oncologist 2002;7(Suppl 5):3-10
topotecan followed by paclitaxel plus carboplatin versus standard carboplatin 31. Peng LH, Chen XY, Wu TX. Topotecan for ovarian cancer. Cochrane Database
plus paclitaxel as first-line chemotherapy in women with newly diagnosed Syst Rev (Online) 2008:CD005589
advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer 32. Garst J. Safety of topotecan in the treatment of recurrent small-cell lung
Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO. J Clin Oncol cancer and ovarian cancer. Exp Opin Drug Safe 2007;6:53-62
2008;26(20S):Abstract LBA 5505 33. Goldwasser F, Buthaud X, Gross M, et al. Decreased topotecan platelet toxicity
12. Gordon AN, Asmar L, Messing MJ, et al. Phase II study of sequential with successive topotecan treatment cycles in advanced ovarian cancer
doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, patients. Anti-cancer Drugs 1999;10:263-5
in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol 34. Eckardt JR. Emerging role of weekly topotecan in recurrent small cell lung
2004;94:533-9 cancer. Oncologist 2004;9(Suppl 6):25-32
13. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second- 35. Morris R, Munkarah A. Alternate dosing schedules for topotecan in the treat-
line treatment of epithelial ovarian cancer: results of a large European phase II ment of recurrent ovarian cancer. Oncologist 2002;(7 Suppl 5):29-35
study. J Clin Oncol 1996;14:3056-61 36. Homesley H, Benigno B, Williams J, et al. A phase I study of weekly topotecan
14. Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous and paclitaxel in previously treated epithelial ovarian carcinoma patients.
topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. Gynecol Oncol 2002;87:171-7
J Clin Oncol 1996;14:1552-7 37. Brown 3rd JV, Rettenmaier MA, Lopez KL, et al. A phase II, multicenter trial
15. Swisher EM, Mutch DG, Rader JS, et al. Topotecan in platinum- and pacli- of weekly topotecan in patients with recurrent platinum-sensitive
taxel-resistant ovarian cancer. Gynecol Oncol 1997;66:480-6 epithelial cancers of the ovary and peritoneum. Int J Gynecol Cancer 2008;
16. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of 18:249-54
advanced epithelial ovarian cancer: an open-label phase II study in patients 38. Largillier R, Valenza B, Ferrero JM, et al. Haematological evaluation of weekly
treated after prior chemotherapy that contained cisplatin or carboplatin and therapy with topotecan for the treatment of recurrent ovarian cancer resistant
paclitaxel. J Clin Oncol 1998;16:3345-52 to platinum-based therapy. Oncology 2007;73:177-84
17. McGuire WP, Blessing JA, Bookman MA, et al. Topotecan has substantial 39. Spannuth WA, Leath 3rd CA, Huh WK, et al. A phase II trial of weekly
antitumor activity as first-line salvage therapy in platinum-sensitive epithelial topotecan for patients with secondary platinum-resistant recurrent epithelial
!
2009 Informa UK Ltd www.cmrojournal.com Topotecan for relapsed ovarian cancer Sehouli & Oskay-O
¨
zcelik
11
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34